Evidence map›Paper›PMID 34479551›Full record

ReviewAnnals of clinical microbiology and antimicrobials2021

An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics.

Ichrak Benamri, Maryame Azzouzi, Kholoud Sanak, Ahmed Moussa, Fouzia Radouani

Open access · goldAbstract readReview
In one paragraph

Review in Annals of clinical microbiology and antimicrobials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Putative azithromycin resistance mutations inAntimicrobial agents and chemotherapy · 2026
    Article
  6. Article
  7. Anti-International journal of molecular sciences · 2026
    Review
  8. Clinical management and pharmaceutical care of severeFrontiers in cellular and infection microbiology · 2026
    Review
  9. Antimicrobial Management of SevereInfection and drug resistance · 2026
    Review
  10. Article
  11. Kaempferol inhibitsFrontiers in microbiology · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. An Atypical Pneumonia Case of Quinolone-RefractoryInfection and drug resistance · 2025
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ichrak BenamriChlamydiae and Mycoplasma Laboratory, Institut Pasteur du Maroc, 20360, Casablanca, Morocco.
Maryame AzzouziChlamydiae and Mycoplasma Laboratory, Institut Pasteur du Maroc, 20360, Casablanca, Morocco.
Kholoud SanakChlamydiae and Mycoplasma Laboratory, Institut Pasteur du Maroc, 20360, Casablanca, Morocco.
Ahmed Moussa *Systems & Data Engineering Team, National School of Applied Sciences, Abdelmalek Essaadi University, Tangier, Morocco.
Fouzia Radouani *Chlamydiae and Mycoplasma Laboratory, Institut Pasteur du Maroc, 20360, Casablanca, Morocco. radouani@gmail.com.
Abdelmalek Essaâdi University · MAInstitut Pasteur du Maroc · MAUniversity of Hassan II Casablanca · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChlamydiae are intracellular bacteria that cause various severe diseases in humans and animals. The common treatment for chlamydia infections are antibiotics. However, when antibiotics are misused (overuse or self-medication), this may lead to resistance of a number of chlamydia species, causing a real public health problem worldwide. MATERIALS AND

methodsIn the present work, a comprehensive literature search was conducted in the following databases: PubMed, Google Scholar, Cochrane Library, Science direct and Web of Science. The primary purpose is to analyse a set of data describing the genes and mutations involved in Chlamydiae resistance to antibiotic mechanisms. In addition, we proceeded to a filtration process among 704 retrieved articles, then finished by focusing on 24 studies to extract data that met our requirements.

resultsThe present study revealed that Chlamydia trachomatis may develop resistance to macrolides via mutations in the 23S rRNA, rplD, rplV genes, to rifamycins via mutations in the rpoB gene, to fluoroquinolones via mutations in the gyrA, parC and ygeD genes, to tetracyclines via mutations in the rpoB gene, to fosfomycin via mutations in the murA gene, to MDQA via mutations in the secY gene. Whereas, Chlamydia pneumoniae may develop resistance to rifamycins via mutations in the rpoB gene, to fluoroquinolones via mutations in the gyrA gene. Furthermore, the extracted data revealed that Chlamydia psittaci may develop resistance to aminoglycosides via mutations in the 16S rRNA and rpoB genes, to macrolides via mutations in the 23S rRNA gene. Moreover, Chlamydia suis can become resistance to tetracyclines via mutations in the tet(C) gene. In addition, Chlamydia caviae may develop resistance to macrolides via variations in the 23S rRNA gene. The associated mechanisms of resistance are generally: the inhibition of bacteria's protein synthesis, the inhibition of bacterial enzymes' action and the inhibition of bacterial transcription process.

conclusionThis literature review revealed the existence of diverse mutations associated with resistance to antibiotics using molecular tools and targeting chlamydia species' genes. Furthermore, these mutations were shown to be associated with different mechanisms that led to resistance. In that regards, more mutations and information can be shown by a deep investigation using the whole genome sequencing. Certainly, this can help improving to handle chlamydia infections and healthcare improvement by decreasing diseases complications and medical costs.

Indexed as

Anti-Bacterial AgentsChlamydia InfectionsChlamydia trachomatisFluoroquinolonesHumansMacrolidesMutationRifamycinsRNA, Ribosomal, 16SRNA, Ribosomal, 23STetracyclinesAnti-Bacterial AgentsFluoroquinolonesMacrolidesRifamycinsRNA, Ribosomal, 16SRNA, Ribosomal, 23STetracyclinesAntibioticsChlamydiaeDatasetGenesInfectionsMutationsResistance

Identifiers

PMID34479551
PMCPMC8414684
OpenAlexW3196976693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.